Health Care Equipment

Nexalin Tech

Nexalin Releases Investor Presentation on Deep Intracranial Frequency Stimulation Technology

Nexalin Technology Faces Significant Business Risks Due to U.S.-China Trade Tensions

Nexalin Tech released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 129.75 K and EPS of USD -0.3779

Nexalin Tech released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 18.15 K (forecast USD 40 K), actual EPS USD -0.1279 (forecast USD -0.12)

Nexalin Publishes Three Studies on DIFS™ Technology for Alzheimer's Treatment

Nexalin Tech released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 70.59 K (forecast USD 35 K), actual EPS USD -0.1005 (forecast USD -0.14)

Nexalin Tech released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 111.6K, actual EPS USD -0.2457

Nexalin Tech released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 41.02 K (forecast USD 35 K), actual EPS USD -0.1494 (forecast USD -0.1)

Nexalin to Initiate Alzheimer's Clinical Trial

Nexalin Technology issues 3.85 million common shares to raise $5 million

Nexalin Technology Inc. Adjusts Its Offering Plan

Nexalin Submits Gen-2 SYNC System Q-Submission to FDA

Nexalin Technology Secures IRB Approval and Launches Clinical Trials in Brazil

Nexalin Technology Announces HALO Platform Completes Five-Stage Research

Bipartisan Bill Expands Medicare Coverage for AI-Powered Medical Devices

Nexalin Obtains Patent, Advancing Non-Invasive Brain Stimulation for Addiction

Nexalin Successfully Recruits First Patients for Clinical Trial

Nexalin Tech released FY2024 Q4 earnings on March 14 (EST), actual revenue 27.18 K USD (forecast 30 K USD), actual EPS -0.2565 USD (forecast -0.12 USD)

Nexalin Tech released FY2024 annual earnings on March 14 (EST), actual revenue 168.72 K USD (forecast 172 K USD), actual EPS -0.8254 USD (forecast -0.61 USD)

Nexalin Obtains New Patent, Enhancing the Potential of DIFS™ Technology in Combating Substance Use Disorders

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap